Lilly wins Alimta patent dispute with vitamin argument
This article was originally published in Scrip
Executive Summary
A US court has ruled in favor of Eli Lilly regarding a patent covering the lung cancer drug Alimta (pemetrexed for injection). The win ensures patent protection for Alimta until 2022. Teva, the challenger, is expected to appeal.